VPC-14449

VPC-14449 is a potent and selective inhibitor of the DNA-binding domain of the androgen receptor (AR-DBD), with IC50 of 0.34 μM for full-length human AR. VPC-14449 reduces the ability of full-length AR as well as AR variants to interact with chromatin. VPC-14449 can be used for the research of prostate cancer[1][2].

Product Specifications

CAS Number

[1621375-32-3]

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/vpc-14449.html

Concentration

10mM

Purity

99.51

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

BrC1=CN(C2=CSC(N3CCOCC3)=N2)C(Br)=N1

Molecular Formula

C10H10Br2N4OS

Molecular Weight

394.09

References & Citations

[1]Dalal K, et, al. Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem. 2014 Sep 19;289 (38) :26417-26429.|[2]Dalal K, et, al. Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions. Mol Cancer Ther. 2017 Oct;16 (10) :2281-2291.